China SXT Pharmaceuticals

SXTC

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$4.10

+0.47 (+12.95%)

Market Cap

$2.2M

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Data as of Aug 23, 2026 · filings through Mar 31, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+1534.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 42K (2022) → 680K (2026)

Winston Score History

The full picture

China SXT Pharmaceuticals makes traditional Chinese medicine (TCM) products and sells them in China. Its core products include concentrated TCM granules, which are processed herbal medicines that dissolve in water and are easier to use than raw herbs. Its main customers are hospitals, clinics, and pharmacies across China.

The company earns money by selling its TCM products directly to healthcare distributors and medical institutions. It operates almost entirely within China and is a small-cap company with a market cap near zero, reflecting serious financial stress — its operating margin is deeply negative, meaning it spends far more than it earns. The biggest risk facing the business is its ongoing inability to turn a profit, and it will need to significantly cut costs or grow revenue to remain a viable company.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+163.0% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+127.5% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$178,765/ year

↓ Declining (-7% vs prior year)

16.7% of revenue

In line with sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

17.5%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~3 years

$28M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

$28M cash & investments at current burn rate

Revenue accelerating

China SXT Pharmaceuticals grew revenue 163% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

17.1%

Thin — 17.1% gross margin

Profit after running costs

Operating Margin

-664.1%

Losing money on operations — -664.1%

Return on the money invested

ROCE

-23.1%

Weak — -23.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-38.4%

Shrinking sales (-38.4% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-374.5%

Burning cash (-374.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.04

Conservative — low debt load (0.04)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial